Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457944 | 1.00 | MAPT (0.59) | MAPTCYP1A2GAARECQLSMN1; SMN2 | |
| SCHEMBL17258327 | 0.90 | MAPT (0.54) | MAPTCYP1A2GAARECQLSMN1; SMN2 | |
| SCHEMBL25434694 | 0.86 | MAPT (0.48) | MAPTCYP1A2GAARECQLSMN1; SMN2 | |
| SCHEMBL69653 | 0.86 | MAPT (0.64) | MAPTCYP1A2GAARECQLSMN1; SMN2 | |
| SCHEMBL31264286 | 0.81 | MAPT (0.55) | MAPTCYP1A2GAARECQLSMN1; SMN2 | |
| SCHEMBL875715 | 0.81 | MAPT (0.55) | MAPTCYP1A2GAARECQLSMN1; SMN2 | |
| SCHEMBL27633761 | 0.81 | GRM5 (0.47) | MAPTCYP1A2GAARECQLSMN1; SMN2 | |
| SCHEMBL594691 | 0.80 | GRM5 (0.44) | MAPTCYP1A2GAARECQLSMN1; SMN2 | |
| SCHEMBL22940095 | 0.80 | MAPT (0.64) | MAPTCYP1A2GAARECQLGRM5 | |
| SCHEMBL31746517 | 0.80 | GRM5 (0.44) | MAPTCYP1A2GAARECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106749189-A | A kind of pyridine radicals bridging NNN bimetallics part and its synthetic method | 中国科学院大连化学物理研究所 | 2017-05-31 | — | — | CN | claimed |
| EP-4225762-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4212523-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260076962-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | NIMMUNE BIOPHARMA, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3867249-B1 | (ISOPROPYL-TRIAZOLYL)PYRIDINYL-SUBSTITUTED BENZOTHIAZINONE DERIVATIVES AS ASK1 INHIBTORS FOR THE TREATMENT OF METABOLIC DISORDERS | HK INNO N CORP (KR) | 2026-03-04 | — | — | EP | disclosed |
| US-12565491-B2 | (Isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | HK INNO.N CORPORATION (KR) | 2026-03-03 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| WO-2002060877-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | WO | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001042217-A1 | BETA-3 ADRENOCEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| US-5502065-A | TREATING HEADACHES | PFIZER INC. (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0636129-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | Pfizer Limited (GB) | 1995-02-01 | — | — | EP | disclosed |
| CN-1082040-A | Indoles | PFIZER RES & DEV (IE) | 1994-02-16 | — | — | CN | disclosed |
| WO-1993021178-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565491-B2 | (Isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | IRAK1, PEAK1, IRAK4 | MAPT 1221/4885CYP1A2 3315/4885GAA 2463/4885 |
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | MAPT 3470/4885CYP1A2 4592/4885GAA 4657/4885 |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, SNCA, ROS1 | MAPT 717/4885CYP1A2 3281/4885GAA 1504/4885 |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, CLIC1 | MAPT 4622/4885CYP1A2 2748/4885GAA 3751/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | MAPT 448/4885CYP1A2 4578/4885GAA 2716/4885 |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | MAPT 3245/4885CYP1A2 167/4885GAA 4354/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | MAPT 4151/4885CYP1A2 2456/4885GAA 4452/4885 |
| US-20260076962-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | SCLY, CLCN2, CBS | MAPT 4651/4885CYP1A2 4799/4885GAA 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.